Nastech Pharmaceutical plans to restructure in order to reduce operating expenses. The company will launch a subsidiary, MDRNA, Inc., as an independent, separately financed company, while the main company will concentrate on Phase II clinical and partnered programs. Steven C. Quay, M.D., Ph.D., chairman, president and chief executive officer of Nastech, remarked, “The establishment of MDRNA as an independent company will better serve our shareholders by providing a structure that will h...